Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Blog
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Before the mission: the military training businesses behind $KTOS, $KOPN, $AVAV and $CAE
Compare Kratos, Kopin, AeroVironment and CAE across training devices, displays, instruction and support, separating prototypes from contracts.
Duchenne: who remains outside the options at $CAPR, $SRPT, $RGNX and $DYN?
Compare Capricor, Sarepta, REGENXBIO and Dyne by mutation, age, walking ability, safety and the difference between trial access and approval.
Sickle cell: what progress means for $AGIO, $CRSP, $BEAM and $NVO
Compare Agios, CRISPR, Beam and Novo Nordisk through hemoglobin, painful crises, transfusions and durable outcomes in sickle cell disease.
MASH beyond weight loss: what $ALT, $VKTX, $IVA and $MDGL actually have to prove
Compare Altimmune, Viking, Inventiva and Madrigal through liver fat, MASH resolution, fibrosis and the evidence still needed beyond weight loss.
Biotech Radar, October 7: regulatory progress, Parkinson’s data and oncology milestones
Five biotech updates, five different kinds of progress: regulatory review, exploratory Parkinson’s data, a Canadian approval and oncology enrollment milestones.
Biotech Radar: $APUS, $AVBP, $JUNS, $OSTX | October 6, 2026
$APUS and $AVBP lead opposite extremes as $JUNS begins Parkinson’s patient dosing and $OSTX reports survival data. The October 6 radar also covers $CNXU, $SCYX, $JAGX and $PCVX.
Anti-infectives: can $CRMD, $INVA, $SPRO and $SCYX turn approvals into durable cash flow?
CorMedix, Innoviva, Spero and SCYNEXIS connect infection prevention, hospital treatment and antifungal development. This analysis separates approved uses, launch plans, royalty rights, reimbursement, reported cash and conditional funding.
Myelofibrosis: $GERN, $INCY, $GSK, $KPTI and the next treatment frontier
Geron’s event-driven survival study, Incyte’s new ruxolitinib formulation, GSK’s anemia-oriented product and Karyopharm’s submitted combination application represent different ways to address myelofibrosis. Their trial populations, endpoint outcomes and funding conditions differ.
Cytokines: $IBRX, $XLO, $CTMX, $MDNAF and the control challenge
Engineered cytokines aim to make powerful immune signals more usable. ImmunityBio, Xilio, CytomX and Medicenna illustrate receptor design, conditional activation and the practical limits imposed by safety, manufacturing and funding.
Plasma: $ADMA, $GRFS, $CSLLY, $TAK and immune protection
ADMA, Grifols, CSL and Takeda compete across a demanding plasma supply chain. This analysis connects approved products and new formulations with manufacturing yield, distribution, working capital and the capital choices behind each equity.
Cell therapy: $IOVA, $LEGN, $GILD, $BMY and the economics of one patient, one batch
Iovance’s September 29 guidance increase puts cell-therapy execution back in focus. Legend, Gilead and Bristol Myers Squibb show why manufacturing capacity, patient access and accounting economics must be analyzed together.
Space Economy: Which of $SIDU, $RKLB, $PL and $BKSY Is Turning Launches Into Cash?
Sidus revises its launch plan as Rocket Lab, Planet and BlackSky advance at different stages. A detailed examination of execution, contracts, financing and cash conversion.
What Could EADV 2026 Change for $NKTR, $ATTO, $INCY and $ARQT in Dermatology?
Nektar and Attovia bring the September 28 news trigger; Incyte and Arcutis supply the clinical and commercial context. A source-based comparison of what the next data can—and cannot—establish.
Drones: Which of $DPRO, $UMAC, $RCAT and $VWAV Is Turning Orders Into Production?
Draganfly’s announced strategic financing links it more closely with Unusual Machines, while Red Cat expands maritime production and VisionWave develops STRATUM. The comparison follows the evidence from conditional orders and qualification to manufacturing, margins, cash and dilution.
GLP-1: What Do the New Data Mean for $LLY, $NVO, $VKTX and $GPCR?
Lilly adds an indirect oral comparison as Viking closes a major financing. A source-led examination of four GLP-1 businesses, their evidence and next milestones.
Retina: Which of $KOD, $FDMT, $OCUL and $EYPT Leads the Race for Longer-Lasting Treatment?
Kodiak’s DAYBREAK results and 4DMT’s new pivotal DME program renew the focus on durable retinal therapies. A source-led comparison with Ocular and EyePoint examines what the data establish, where trial designs differ, and how funding changes the path to the next catalyst.
$CAPR | Capricor Therapeutics Total Catalyst Map
$CAPR Total Catalyst Map: Capricor Therapeutics FDA date, HOPE-3, WMS, cash, partnerships and 2026–2027 milestones, verified against primary sources.
A packed catalyst roadmap for these 5 hot biotech stocks
Five biotech stocks face a packed calendar of clinical data and FDA decisions. This map separates major evidence from presentations and study starts without inflating correlated events.
$DRTS — Total Catalyst Map
Alpha Tau Medical ($DRTS): 18 catalysts, 2026–2027 timelines, clinical readouts, FDA milestones, Tolmar, Japan and potential stock impact.
Getting medicines into the brain: shuttles, vectors and direct delivery | $DNLI, $QURE, $RHHBY, $VYGR
How $DNLI, $QURE, $RHHBY and $VYGR approach brain delivery: molecular shuttles, systemic vectors and direct infusion, from biomarkers to clinical benefit.
